cannabinoid

InMed Pharmaceuticals is making strides in Alzheimer’s research with its development of a cannabinoid-based compound that aims to protect and rejuvenate brain neurons. During Benzinga’s virtual event on Thursday, InMed president and CEO Eric A. Adams shared detailed insights into the...

Incannex Healthcare Limited (NASDAQ: IXHL) has completed a preliminary analysis of data from its Phase 2 trial of a cannabinoid combination product, IHL-42X, for obstructive sleep apnoea (OSA). The clinical trial assessed three doses of IHL-42X at reducing the apnoea hypopnoea index...

Lexaria Bioscience Corp (NASDAQ: LEXX) has issued follow-up results from human clinical study HYPER-H21-2 of DehydraTECH-processed cannabidiol (CBD). The data showed that after a single day of dosing, the processed CBD reduced arterial stiffness, potentially broadening its...

InMed Pharmaceuticals Inc (NASDAQ: INM) reported an FY21 EPS loss of $(1.52) narrower than $(1.71) posted a year ago. On June 30, the company's cash, cash equivalents, and short-term investments were $7.4 million. R&D and patents expenses were $5.3 million compared to $5.8...

Lexaria Bioscience Corp (NASDAQ: LEXX) has announced initial results from human clinical study HYPER-H21-2 evaluating DehydraTECH-processed cannabidiol (CBD) for potential application against hypertension.  Related Content: DehydraTECH Delivered Colchicine Can Potentially Treat...

The FDA has signed off Cardiol Therapeutics Inc's (NASDAQ: CRDL) Investigational New Drug (IND) application for CardiolRx. Cardiol will commence a Phase 2, multi-center, double-blind, randomized, placebo-controlled trial to assess the safety and tolerability of CardiolRx in...

Canadian-based CBD and THC extraction company Nextleaf Solutions Ltd. (OTC: OILFF)(CSE: OILS) expanded its intellectual property (IP) collection with the issuance of new patents. What Happened The recently issued patents expand Nextleaf's portfolio, which includes 24 additional issuances, with...

Consumer cannabidiol company cbdMD Inc (NYSE: YCBD) announced Tuesday a new partnership with retired NFL players Steve Smith, Sr. and Jonathan Stewart. What Happened Smith and Stewart played together with the Carolina Panthers and are now reunited through a new partnership with cbdMD, best known...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a company that focuses on treating rare and near-rare neuropsychiatric disorders through cannabinoid therapies, said Tuesday it received a new U.S. patent for one of its cannabis-focused treatments. Zynerba said the U.S. Patent and Trademark Office...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) announced Thursday its Phase 2 trial for ZYN002 in Fragile X syndrome found sustained improvements in patients’ core behavioral symptoms. The drug was well tolerated with no serious adverse events. Why It’s Important The candidate is the most...

Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a specialty pharmaceutical company that focuses on developing and commercializing pharmaceutically produced transdermal cannabinoid treatments, traded higher during Monday's pre-market session but then sold off after the opening bell. The...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), which specializes in transdermal synthetic cannabinoid treatments, has a 25-percent probability for success in its treatment of adult epilepsy, an analyst said Tuesday. Cantor Fitzgerald analyst Elemer Piros said there were no surprises in the Q2 results...

Cantor Fitzgerald has raised its price target on GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) to $208/ADS from $182/ADS after additional positive Epidiolex results. Epidiolex Significance The recent data of Epidiolex presented at the American Epilepsy Society (AES) event showed “robustness and...

Cannabinoid drug developer GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) is ending an eventful 2016 on a high note. Shares were surging higher by 6.6 percent on Monday following new drug data out over the weekend and a strong fiscal Q4 earnings report out Monday. Over the weekend, the company reported...

The surprise election of Donald Trump has gotten most of the election-related headlines following Tuesday’s vote. However, Tuesday was also a landmark day for the marijuana legalization movement. Marijuana scored medical and/or recreational victories in eight of the nine states that voted on...